CA2643747A1 - Autoimmune conditions and nadph oxidase defects - Google Patents
Autoimmune conditions and nadph oxidase defects Download PDFInfo
- Publication number
- CA2643747A1 CA2643747A1 CA002643747A CA2643747A CA2643747A1 CA 2643747 A1 CA2643747 A1 CA 2643747A1 CA 002643747 A CA002643747 A CA 002643747A CA 2643747 A CA2643747 A CA 2643747A CA 2643747 A1 CA2643747 A1 CA 2643747A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- integer
- alkynyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001363 autoimmune Effects 0.000 title claims abstract 7
- 102000004722 NADPH Oxidases Human genes 0.000 title abstract 2
- 108010002998 NADPH Oxidases Proteins 0.000 title abstract 2
- 230000007547 defect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- ZGIGZINMAOQWLX-UHFFFAOYSA-N Farnesyl acetate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOC(C)=O ZGIGZINMAOQWLX-UHFFFAOYSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 claims 1
- KEVYVLWNCKMXJX-UHFFFAOYSA-N 3,7,11,15-tetramethylhexadec-1-en-3-ol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C=C KEVYVLWNCKMXJX-UHFFFAOYSA-N 0.000 claims 1
- ZGIGZINMAOQWLX-NCZFFCEISA-N 3,7,11-Trimethyl-2,6,10-dodecatrienyl acetate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\COC(C)=O ZGIGZINMAOQWLX-NCZFFCEISA-N 0.000 claims 1
- URHFTVMWWAYVFR-UHFFFAOYSA-N 6-(difluoromethoxy)-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromene Chemical compound FC(F)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C URHFTVMWWAYVFR-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- KEVYVLWNCKMXJX-ZCNNSNEGSA-N Isophytol Natural products CC(C)CCC[C@H](C)CCC[C@@H](C)CCC[C@@](C)(O)C=C KEVYVLWNCKMXJX-ZCNNSNEGSA-N 0.000 claims 1
- JIGCTXHIECXYRJ-LTGZKZEYSA-N Phytyl acetate Chemical compound CC(C)CCCC(C)CCCC(C)CCC\C(C)=C\COC(C)=O JIGCTXHIECXYRJ-LTGZKZEYSA-N 0.000 claims 1
- JIGCTXHIECXYRJ-ILWBRPEASA-N [(e,7r,11r)-3,7,11,15-tetramethylhexadec-2-enyl] acetate Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\COC(C)=O JIGCTXHIECXYRJ-ILWBRPEASA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940007703 farnesyl acetate Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- JIGCTXHIECXYRJ-UHFFFAOYSA-N trans-phytol acetate Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=CCOC(C)=O JIGCTXHIECXYRJ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002298 terpene group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to methods and materials involved in treating autoimmune conditions. In particular, the invention relates to methods and compounds (and compositions including the compounds) involved in treating, preventing, or delaying the onset of autoimmune conditions. The compounds can include one or more isoprenoid units. The compounds can enhance NADPH oxidase activity.
Claims (25)
1. Use of a compound wherein the compound has the following general formula:
m + n = an integer from 0-9;
X is selected from wherein represents a single or double bond between C2 and C3;
Y is -O-C(==O)R';
R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, on heteroaryl, each of which is optionally substituted; and R'' is H, alkyl, alkenyl, alkynyl or cycloalkyl, each of which is optionally substituted;
in the manufacture of a medicament for the treatment of an autoimmune condition.
m + n = an integer from 0-9;
X is selected from wherein represents a single or double bond between C2 and C3;
Y is -O-C(==O)R';
R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, on heteroaryl, each of which is optionally substituted; and R'' is H, alkyl, alkenyl, alkynyl or cycloalkyl, each of which is optionally substituted;
in the manufacture of a medicament for the treatment of an autoimmune condition.
2. The use according to claim 1, wherein the compound has the general formula:
wherein:
m + n = an integer from 0-9;
represents a single or double bond between C2 and C3; and Y is -O-C(=O)R', wherein R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl; or heteroaryl, each of which is optionally substituted.
wherein:
m + n = an integer from 0-9;
represents a single or double bond between C2 and C3; and Y is -O-C(=O)R', wherein R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl; or heteroaryl, each of which is optionally substituted.
3. The use of claim 2, wherein R' is C1-C~ alkyl.
4, The use of claim 3, wherein R' is CH3.
5. The use of claim 2, wherein ~ + n = an integer from 0-5.
6. The use of claim 1, wherein one of m and n is 0, and the other is an integer from 1-5.
7. The use of claim 1, wherein m + n = 3.
8. The use of claim 7, wherein one of m and n is 0.
9. The use of claim 8, wherein n is 0.
10. The use of claim 2, wherein m + n = 2.
11. The use of claim 2, wherein represents a double bond between C2 and C3.
12. The use of claim 2, wherein the compound is selected from the group consisting of:
Farnesyl acetate (Acetic acid 3,7,11-trimethyl-dodeca-2,6,10-trienyl ester);
Phytyl acetate (Acetic acid 3,7,11,15-tetra-methyl-hexadec-2-enyl-ester);
Di-hydro-phytol (3,7,11,25-Tetramethyl-hexadecan-1-ol); and Di-hydro-phytyl acetate (Acetic acid 3,7,11,15-tetramethyl-hexadecyl ester);
Farnesyl acetate (Acetic acid 3,7,11-trimethyl-dodeca-2,6,10-trienyl ester);
Phytyl acetate (Acetic acid 3,7,11,15-tetra-methyl-hexadec-2-enyl-ester);
Di-hydro-phytol (3,7,11,25-Tetramethyl-hexadecan-1-ol); and Di-hydro-phytyl acetate (Acetic acid 3,7,11,15-tetramethyl-hexadecyl ester);
13. The use according to claim 1, wherein the compound has the general formula:
wherein n+m= an integer from 0 to 9; and R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted.
wherein n+m= an integer from 0 to 9; and R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted.
14. The use of claim 13, wherein m + n = 3
15. The use of claim 14, wherein n is 0.
16. The use of claim 13, wherein R' is hydrogen.
17. The use of claim 13, wherein the compound is 3,7,11,15-tetramethyl-1-hexadecen-3-ol.
18 . The use according to claim 1, wherein the compound has the general formula:
wherein n+m= an integer from 0 to 9, and R'' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted.
wherein n+m= an integer from 0 to 9, and R'' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted.
19. The use of claim 18, wherein m + n = 3.
20. The use of claim 19, wherein n is 0.
21. The use of claim 18, wherein R" is C1-C3 alkyl substituted with from 1-3 halogens.
22. The use of claim 18, wherein the compound is 6-difluoromethoxy-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-tridecyl)-chroman.
23. The use of any one of claims 1 to 22, wherein said autoimmune condition is arthritis.
24. The use of any one of claims 1 to 22, wherein said autoimmune condition is multiple sclerosis.
25. The use of any one of claims 1 to 22, wherein said autoimmune condition is inflammatory bowel disease.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78238106P | 2006-03-15 | 2006-03-15 | |
| US60/782,381 | 2006-03-15 | ||
| PCT/EP2007/052457 WO2007104790A1 (en) | 2006-03-15 | 2007-03-15 | Autoimmune conditions and nadph oxidase defects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2643747A1 true CA2643747A1 (en) | 2007-09-20 |
Family
ID=38236360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002643747A Abandoned CA2643747A1 (en) | 2006-03-15 | 2007-03-15 | Autoimmune conditions and nadph oxidase defects |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2004159A1 (en) |
| JP (1) | JP2010521412A (en) |
| KR (1) | KR20090008233A (en) |
| CN (1) | CN101404985A (en) |
| AU (1) | AU2007224438B2 (en) |
| CA (1) | CA2643747A1 (en) |
| NZ (1) | NZ570803A (en) |
| WO (1) | WO2007104790A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201104600D0 (en) | 2011-03-18 | 2011-05-04 | Pronoxis Ab | New compounds and medical uses |
| US10780061B2 (en) | 2014-09-26 | 2020-09-22 | Daegu Gyeongbuk Institute Of Science And Technology | Composition comprising farnesol and use thereof |
| RU2631887C2 (en) * | 2015-09-07 | 2017-09-28 | Вагиф Султанович Султанов | Active drug ingredient, drug, pharmaceutical composition and method for treatment of demyelinating diseases of living organism, including disease prevention |
| FR3110427B1 (en) * | 2020-05-20 | 2023-07-14 | Laboratoires Eriger | Coupling terpene conjugate |
| JP2024501949A (en) * | 2020-12-23 | 2024-01-17 | アクセス ツー アドバンスト ヘルス インスティチュート | Solanesol vaccine adjuvant and its preparation method |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61257944A (en) * | 1986-03-20 | 1986-11-15 | Nisshin Flour Milling Co Ltd | Remedy for ulcer |
| US4983637A (en) * | 1988-06-24 | 1991-01-08 | Stephen Herman | Method for treating viral infection of HIV |
| US5475029A (en) * | 1993-07-08 | 1995-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Farnesyl compounds as cholesterol lowering agents |
| JPH10168090A (en) * | 1996-12-11 | 1998-06-23 | Eisai Co Ltd | Apoptotic inducer |
| US6703384B2 (en) * | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| JP2001172171A (en) * | 1999-10-06 | 2001-06-26 | Kazuhito Rokutan | Revulsive for heat shock protein |
| GB0019290D0 (en) * | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| JP4578235B2 (en) * | 2002-05-13 | 2010-11-10 | アレクシス・アクチボラゲット | Autoimmune status and NADPH oxidase deficiency |
| KR20070044805A (en) * | 2004-04-15 | 2007-04-30 | 키아스마, 인코포레이티드 | Compositions That Can Promote Biological Barrier Permeation |
| FR2869230B1 (en) * | 2004-04-23 | 2006-07-28 | Alessio Patrizia D | COMPOSITION FOR PREVENTING OR TREATING CELL DEGENERATION WITH AT LEAST ONE MOLECULE CAPABLE OF MAINTAINING THE REVERSIBILITY OF ADHESION MOLECULE EXPRESSION AND POLYMERIZATION OF ACTIN FIBERS |
-
2007
- 2007-03-15 JP JP2008558825A patent/JP2010521412A/en active Pending
- 2007-03-15 CA CA002643747A patent/CA2643747A1/en not_active Abandoned
- 2007-03-15 NZ NZ570803A patent/NZ570803A/en not_active IP Right Cessation
- 2007-03-15 WO PCT/EP2007/052457 patent/WO2007104790A1/en not_active Ceased
- 2007-03-15 AU AU2007224438A patent/AU2007224438B2/en not_active Ceased
- 2007-03-15 EP EP07726945A patent/EP2004159A1/en not_active Withdrawn
- 2007-03-15 KR KR1020087025212A patent/KR20090008233A/en not_active Ceased
- 2007-03-15 CN CNA2007800093023A patent/CN101404985A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010521412A (en) | 2010-06-24 |
| WO2007104790A1 (en) | 2007-09-20 |
| CN101404985A (en) | 2009-04-08 |
| KR20090008233A (en) | 2009-01-21 |
| AU2007224438A1 (en) | 2007-09-20 |
| AU2007224438B2 (en) | 2012-07-26 |
| NZ570803A (en) | 2011-06-30 |
| EP2004159A1 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2643747A1 (en) | Autoimmune conditions and nadph oxidase defects | |
| Golumbic et al. | Antioxidants and the autoxidation of fats. XIII. The antioxygenic action of ascorbic acid in association with tocopherols, hydroquinones and related compounds | |
| ATE314060T1 (en) | TRIARYLMETHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSIARCOMA | |
| BRPI0408228A (en) | cytokine inhibitors | |
| WO2005000860A3 (en) | Compositions and methods for treatment of disease with acetylated disaccharides | |
| WO2010078330A4 (en) | Catalyst composition with phosphorus-based donor | |
| MA31078B1 (en) | COLLECTOR FOR FLOTATION OF CARBONATES. | |
| WO2008096586A1 (en) | Novel methylated catechin and composition containing the same | |
| CA2459482A1 (en) | Novel glycolipid and medicine for autoimmune disease containing the same as active ingredient | |
| RU2008121713A (en) | CONTROL OF STABILITY OF THE MEDICINAL FORM CCI-779 BY MEANS OF CONTROL OF THE IMPURITIES OF THE MEDICINE | |
| DE3671228D1 (en) | 13-HALOGENED MILBEMYCINE DERIVATIVES, THEIR PRODUCTION AND THE COMPOSITIONS CONTAINING THEM. | |
| KR880008985A (en) | Prostaglandin E and antiulcers containing it | |
| MA41494A (en) | BENZOXABOROLE COMPOUNDS SUBSTITUTED IN POSITION 4 AND ASSOCIATED USES | |
| CN1612731A (en) | Composition for inhibiting matrix-metalloproteinase and treating tumor diseases | |
| Yi et al. | The glucose-6-phosphate dehydrogenase Mahidol variant protects against uncomplicated Plasmodium vivax infection and reduces disease severity in a Kachin population from northeast Myanmar | |
| MA37868B1 (en) | Phosphate ore processing composition | |
| YU40798A (en) | Benzopyran derivatives having leukotriene-antagonistic action | |
| DK1383756T3 (en) | Coumarin derivatives for use as anticoagulants | |
| JP2008509939A5 (en) | ||
| CA2525486A1 (en) | Composition for lowering the internal lipid | |
| ATE486111T1 (en) | CROSS-LINKABLE ADHESIVE FOR REMOVABLE SOFT PVC SUPPORTS | |
| CA2141652A1 (en) | Fluorinated vitamin d3 derivative | |
| WO2009119873A3 (en) | Plant disease controlling composition and method for controlling plant disease | |
| WO2003033507A1 (en) | Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same | |
| TN2011000237A1 (en) | ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140317 |